Atisama Therapeutics said its lead candidate RB042 has advanced into multiple ascending dose cohorts in a…
Drug Development
Atea Pharmaceuticals Holds Q1 2026 Earnings Call as Investors Look for Updates on Clinical Strategy
Atea Pharmaceuticals held its first-quarter 2026 earnings call on May 12, giving investors a routine update…
IDEAYA Biosciences Discusses Strategy and Clinical Pipeline at Bank of America Healthcare Conference 2026
IDEAYA Biosciences participated in the Bank of America Global Healthcare Conference 2026, placing the clinical-stage biotech…